EDIT - Editas Medicine, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 5.32

Open

$ 5.20

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 5.14 - $ 5.40

52 Week Range

$ 5.11 - $ 11.91

Volume

1,352,190

Average Volume

Market Cap

404.14M

Beta (5Y Monthly)

$ 1.52

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-28-2024	12-31-2023	10-K
2	11-03-2023	09-30-2023	10-Q
3	08-02-2023	06-30-2023	10-Q
4	05-05-2023	03-31-2023	10-Q
5	02-22-2023	12-31-2022	10-K
6	11-02-2022	09-30-2022	10-Q
7	08-03-2022	06-30-2022	10-Q
8	05-04-2022	03-31-2022	10-Q
9	02-24-2022	12-31-2021	10-K
10	11-09-2021	09-30-2021	10-Q
11	08-05-2021	06-30-2021	10-Q
12	05-06-2021	03-31-2021	10-Q
13	02-26-2021	12-31-2020	10-K
14	11-06-2020	09-30-2020	10-Q
15	08-07-2020	06-30-2020	10-Q
16	05-08-2020	03-31-2020	10-Q
17	02-26-2020	12-31-2019	10-K
18	11-12-2019	09-30-2019	10-Q
19	08-07-2019	06-30-2019	10-Q
20	05-08-2019	03-31-2019	10-Q
21	03-01-2019	12-31-2018	10-K
22	11-08-2018	09-30-2018	10-Q
23	08-07-2018	06-30-2018	10-Q
24	05-04-2018	03-31-2018	10-Q
25	03-08-2018	12-31-2017	10-K
26	11-08-2017	09-30-2017	10-Q
27	08-09-2017	06-30-2017	10-Q
28	05-15-2017	03-31-2017	10-Q
29	03-03-2017	12-31-2016	10-K
30	11-09-2016	09-30-2016	10-Q
31	08-10-2016	06-30-2016	10-Q
32	05-13-2016	03-31-2016	10-Q
33	03-30-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Editas Medicine To Present Pre-Clinical Da...
04/22/2024 20:33:55

Editas Medicine presentations at ASGCT include:Oral presentation of in vivo pre-clinical data from mouse studies using lipid na...

The Latest Analyst Ratings For Editas Medi...
02/29/2024 17:00:24

Citigroup Maintains Buy on Editas Medicine...
02/29/2024 16:57:18

Citigroup analyst Samantha Semenkow maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $11 ...

Barclays Maintains Equal-Weight on Editas ...
02/29/2024 13:44:38

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $10 ...

why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Bumble Shares Are Trading Lower By 12%...
02/28/2024 19:02:02

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Advance Auto Parts Reports Q4 Results, Joi...
02/28/2024 16:37:58

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.

Editas Medicine Q4 EPS $(0.23) Beats $(0.5...
02/28/2024 12:02:34

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.5...

Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

JP Morgan Maintains Neutral on Editas Medi...
02/27/2024 18:02:22

JP Morgan analyst Brian Cheng maintains Editas Medicine (NASDAQ:EDIT) with a Neutral and raises the price target from $8 to $9.

Earnings Outlook For Editas Medicine
02/27/2024 18:01:38

Editas Medicine Highlights 2024 Anticipate...
01/08/2024 13:35:45

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical t...

Editas Medicine Announced It Entered Into ...
12/13/2023 14:06:09

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Edi...

The Latest Analyst Ratings for Editas Medi...
12/12/2023 16:00:18

Truist Securities Maintains Buy on Editas ...
12/12/2023 15:13:15

Truist Securities analyst Joon Lee maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $15 t...

Editas Medicine Announces New EDIT-301 Saf...
12/11/2023 17:04:48

All RUBY patients with ≥5 months follow-up have achieved a normal hemoglobin level and a fetal hemoglobin level of >40%All p...

why-fortinet-shares-are-trading-lower-by-around-17-here-are-other-stocks-moving-in-fridays-mid-day-session

Why Fortinet Shares Are Trading Lower By A...
11/03/2023 17:26:11

Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.

Expedia Group, Gartner, Cloudflare, Cardin...
11/03/2023 15:30:22

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in ...

Earnings Scheduled For November 3, 2023
11/03/2023 11:12:01

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per ...

Editas Medicine's Cash, Cash Equivalents, ...
11/03/2023 11:04:29

Editas Medicine Q3 EPS $(0.55) Beats $(0.5...
11/03/2023 11:02:47

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.5...